Orthocell Ltd
OCC
Company Profile
Business description
Orthocell Ltd is engaged in the development, manufacture and commercialisation of collagen-based medical devices and cell therapies for the repair and regeneration of bone, nerve, tendon and cartilage defects. It has one segment regenerative medicine industry in Australia with products sold in Australia and internationally. Its solutions are Remplier, Striate, and Cell Therapies.
Contact
161 Campus Drive
Level 2, Murdoch University
Murdoch
PerthWA6150
AUST: +61 893602888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 17.10 | -0.18% |
| CAC 40 | 8,342.51 | 9.64 | 0.12% |
| DAX 40 | 26,694.28 | 31.51 | 0.12% |
| Dow JONES (US) | 52,420.14 | 66.35 | -0.13% |
| FTSE 100 | 10,823.90 | 11.57 | -0.11% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,305.88 | 160.31 | -0.63% |
| Nikkei 225 | 60,819.36 | 429.23 | -0.70% |
| NZX 50 Index | 14,259.23 | 79.37 | 0.56% |
| S&P 500 | 7,587.90 | 31.48 | -0.41% |
| S&P/ASX 200 | 9,146.80 | 6.40 | -0.07% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |